Abstract:Objective:To observe the adverse reactions caused by different doses of N-acetylcysteine(NAC) in treatment of patients with severe liver diseases for an approach to the drug safe use.Methods:Between February 2006 and January 2008,173 patients with various patterns of severe liver diseases in our hospital were enrolled in the study.One hundred and seventy-three patients were divided into 3 groups:the high-dose group(25 cases),the low-dose group(66 cases),and the dose-escalation group(82 cases).The high-dose group comprised 16 men and 9 women with average age(42.3±3.6) years.The low-dose group comprised 42 men and 24 women with average age(41.6±4.8) years.The dose-escalation group comprised 51 men and 31 women with average age(45.2±5.2) years.The drug administration was as follows:the patients in the high-dose group were administered an IV infusion of NAC 8 g dissolved in 10% glucose 250 ml once daily;the patients in the low-dose group were administered NAC 4 g dissolved in 10% glucose 250 ml once daily,while oral famotidine 20 mg twice daily and slowly IV push of 10% calcium gluconate 10 ml mixed with 50% glucose 20 ml were given.The patients in the dose-escalation group received an initial dose of IV NAC 4 g/d,and if no adverse reaction occurred,the dose of NAC was increased to 8 g/d on day 4.The administration and other medications were the same as those in the low-dose group.All patients were observed at least two weeks.Results:In the high-dose group,adverse reactions occurred in 16 cases(64%) of 25 patients including 9 cases(36%) of skin disorders,2 cases(8%) of chest distress and dizziness,3 cases(12%) of gastrointestinal disorders,one case(4%) of anaphylactic shock,and one case(4%) of lower limbs dyskinesia.The Model for End-Stage Liver Disease(MELD) scores to the patients experiencing adverse reactions and the patients no experiencing adverse reactions in the high-dose group were 11.26±5.47 and 18.38±5.71,respectively.The difference was statistically significant(P<0.05).It indicated that the condition of patients experiencing adverse reactions was mild.In the low-dose group,adverse reactions occurred in 2 cases(3.03%) of 66 patients including 1 case of rash,and 1 case of upper abdominal discomfort.The incidence of adverse reactions in the low-dose group was lower than that in the high-dose group.The difference was statistically significant(P<0.001).The MELD scores in the patients experiencing rash and the patients experiencing upper abdominal discomfort were 11.38 and 10.29,respectively.In the dose-escalation group,4 patients(4.88%) developed adverse reactions within 3 days of treatment;seven(8.97%) of other 78 patients developed adverse reactions in more than 4 days of treatment,and the incidence was higher than the low-dose group and lower than the high-dose group(all P<0.001).Of the 78 patients,31 patients'MELD score was >15,and one case of gastrointestinal disorders and one case of skin rash occurred;47 patients'MELD score was <15,and 3 case of gastrointestinal disorder,one case of scalp swelling and one case of skin rash occurred.The difference between both of them was statistically significant(P< 0.001).The patients'adverse reactions disappeared after discontinuation of the drug and symptomatic treatment.Conclusion:Low-dose or dose-escalation NAC combined with oral famotidine and IV calcium gluconate 10% is a safe regimen in treatment of severe liver diseases,but relatively mild cases of severe liver diseases should be closely monitored during treatment in order to avoid or decrease adverse reaction occurring.

N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review

N-Acetylcysteine for Preventing Acetaminophen-Induced Liver Injury: A Comprehensive Review

N-acetylcysteine for non-acetaminophen induced acute liver failure: A review

Drug-Induced Liver Injury: Clinical Evidence of N-Acetyl Cysteine Protective Effects

An Analysis of the Efficacy and Safety of Compound Glycyrrhizin Injections in the Treatment of Drug-Induced Liver Injury Using a Nationwide Database.

Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review

S4269 A K(NAC)K for DILI

The Use and Potential Benefits of N-Acetylcysteine in Non-Acetaminophen Acute Liver Failure: An Etiology-Based Review

A study to evaluate the hepatoprotective effect of N- acetylcysteine on anti tuberculosis drug induced hepatotoxicity and quality of life

Management of Acute Hepatotoxicity Including Medical Agents and Liver Support Systems

A metabolomic analysis of thiol response for standard and modified N-acetyl cysteine treatment regimens in patients with acetaminophen overdose

Study on clinical safety of different doses of N-acetylcysteine in treatment of patients with severe liver diseases

Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review

A Clinical Course of Repeated Supratherapeutic Ingestion of Acetaminophen

Secular Trends in Severe Idiosyncratic Drug-Induced Liver Injury in North America: An Update From the Acute Liver Failure Study Group Registry

Clinical features of drug-induced liver failure and related diagnosis and treatment strategies

Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]

The Potential Role of Efficacy and Safety Evaluation of N-Acetylcysteine Administration During Liver Procurement. The NAC-400 Single Center Randomized Controlled Trial

Network meta-analysis of different liver protective drugs in the treatment of drug-induced liver injury

25-Hydroxycholesterol 3-Sulfate Recovers Acetaminophen Induced Acute Liver Injury via Stabilizing Mitochondria in Mouse Models

The efficacy of Ursodeoxycholic acid therapy on moderate or severe drug-induced liver injury